Here is a data-driven look at Jenburkt Pharmaceuticals (JENBURKT), covering financial performance, valuation, and shareholding trends.
Jenburkt Pharma Revenue Trend
Compared to ₹142 Cr in FY2024, Jenburkt Pharmaceuticals's FY2025 revenue of ₹152 Cr marks a 6.9% improvement.
Revenue compounded at 5.9% annually over 10 years for Jenburkt Pharmaceuticals. It's a reasonable growth rate that's roughly kept pace with the broader market.
With a top line of ₹152 Cr, Jenburkt Pharmaceuticals operates at a smaller scale within the pharmaceuticals sector.
With 4 straight years of revenue growth, this isn't a blip — the trajectory is clear for Jenburkt Pharmaceuticals.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹152 Cr | +6.9% |
| FY2024 | ₹142 Cr | +3.8% |
| FY2023 | ₹137 Cr | +10.3% |
| FY2022 | ₹124 Cr | +9.1% |
| FY2021 | ₹114 Cr | — |
View Jenburkt Pharmaceuticals's full 10-year revenue trend with CAGR analysis →
Jenburkt Pharma Profitability
Earnings came in strong at ₹32.1 Cr for FY2025, marking a 23.4% gain over the ₹26.0 Cr posted in FY2024.
A stronger net margin of 21.1% in FY2025 (from 18.3%) points to better profitability per rupee of revenue.
Looking at per-share numbers, diluted EPS was ₹72.65 in FY2025 — up from ₹58.86.
Is Jenburkt Pharma Undervalued
Jenburkt Pharmaceuticals shares are currently trading at ₹1,090.75.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Jenburkt Pharma Shareholding Pattern
Promoters continue to hold 46.6% of the company, unchanged over recent quarters.
No movement from FIIs — their 0.0% holding is unchanged year-over-year.
The DII stake is flat at 0.1% as of June 2026, unchanged from the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 46.6% | 0.0% | 0.1% | 53.3% |
| Mar 2026 | 46.6% | 0.0% | 0.1% | 53.2% |
| Dec 2025 | 46.6% | 0.0% | 0.1% | 53.2% |
| Sep 2025 | 46.7% | 0.0% | 0.1% | 53.2% |
Track quarterly shareholding changes for Jenburkt Pharmaceuticals →
Jenburkt Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹1.96B (up 18.8% YoY from ₹1.65B).
Top categories: Other Assets (35.0%), Property, Plant & Equipment (26.8%), Cash & ST Investments (12.6%).
Of the ₹1.96B in liabilities and equity, 87.6% is shareholder equity, 2.0% is interest-bearing debt, and 10.5% is operating liabilities. Notable shift: Equity is up 18.5% YoY (₹1.45B → ₹1.72B).
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 246.46M |
| Receivables | 207.35M |
| Inventories | 88.80M |
| Property, Plant & Equipment | 525.71M |
| Investments | 205.58M |
| Intangibles & Goodwill | 2.28M |
| Other Assets | 685.67M |
| Category | Value |
|---|---|
| Equity | 1.72B |
| Short-term Debt | 24.02M |
| Long-term Debt | 14.92M |
| Trade Payables | 81.55M |
| Other Liabilities | 123.60M |
Jenburkt Pharma Key Highlights
Bringing the key threads together for Jenburkt Pharmaceuticals (JENBURKT) as a pharmaceuticals investment opportunity.
Revenue of ₹152 Cr in FY2025, up 6.9% year-over-year.
Long-term revenue has been compounding at 5.9% annually over 10 years.
The company is profitable, with a net margin of 21.1% and net income of ₹32.1 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Jenburkt Pharmaceuticals.